TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean change in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic-type reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative change in hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Emptying (GE t-1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Motor function assessed on Fugl-Meyer Assessment (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Symptoms Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perifoveal vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Threshold Response (in seconds) - Cold Pressor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Tolerance Response (in seconds) - Cold Pressor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Threshold Response (in seconds) - Quantitative Sensory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Tolerance Response (in seconds) - Quantitative Sensory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slow wave sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Progression-free survival after first line treatment
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction with the appearance of penis at 18 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the appearance of penis at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mixed Meal Tolerance Test (MMTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VO2peak Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The 6-minute Push Test (6MPT) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obesity of the Child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: drug use (inhalative steroids and betamimetics)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hospital treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Lymphocyte characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LTB4/LTB5 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of All-cause Death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Non-fatal Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need for Mechanical Support for Severe Left Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Surgical case completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacokinetic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations Above or Equal to Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects With Anti-hepatitis B Antibody Concentrations Above or Equal to Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local and systemic solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Bacterial Growth Before and After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Bacterial Growth 3 Weeks After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of Insulin Aspart
Endpoint domain: Adverse events/effects
Primary endpoint: Culturable aerosols of NTM during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Usability of the LV VectorOpt feature
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SADE free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in Extent of Left Ventricular Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AIIS morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worry levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically Successful Weight Loss of ≥30% Excess Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Back Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Serum Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Study Participants Achieving Menactra Response for Meningococcal Serogroups A, C, Y, and W-135
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations of Pertussis Vaccine Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Pertussis Vaccine Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Antibody Responses to Diphtheria, Tetanus and Polyribosylribitol Phosphate Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in SF-36 Mental Health Component Summary score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histologic diagnostic of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Opioid Consumption in Morphine Opioid Equivalents in mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Salivary Progesterone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Cannabis Withdrawal Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MOS-HIV Health Survey Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Score at 30 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of weekly cluster headache attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Urinary Incontinence Episodes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bulk T Cell Proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of case manager visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in A1C at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Seroprotected Subjects for Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relief of IBS Pain and Discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Serious Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unexpected Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall patient satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to onset of analgesic effect after the first use of the drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Anxiety Rating Scale (SIGH-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in bone mineral density of the lumbar spine (L2-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Site Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: World Health Organization (WHO) Performance Status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diptheria Toxoid Antibody Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median absolute predictive error (MdAPE) without covariates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median absolute predictive error (MdAPE) with renal markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intracranial pressure variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Elevated levels of tumor marker CA-125
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response to immune tolerance induction (ITI) treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of gagging during probe insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Glucagon-like peptide-1 (GLP-1) secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastric Inhibitory Peptide (GIP) secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cholecystokinin (CCK) secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for assistance to enhance services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: vital signs (heart rate and blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Wrist Morning Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of intraoperative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Digital Temperature Difference From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate to oxaliplatin at first progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response rate to oxaliplatin at second or later relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-hospitalization for acute pancreatitis
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ability to PO after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Right cardiac performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate and severity of stage 2-4 GI acute (a)GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate and severity of all grade aGVHD and chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of compliance with GFD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Following a Total Ankle Replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Health Following a Total Ankle Replacement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Limitations Following a Total Ankle Replacement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in allopregnanolone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of PCR from positive to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in total score on European INPH scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Candida albicans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 90-day survival without clinical or microbiological failure
Endpoint domain: Mortality/survival
Primary endpoint: Number of CTCAE grade 3-5 events
Endpoint domain: Adverse events/effects
Primary endpoint: Physical functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum bone turnover biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse for worsening asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Systolic function indices measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Diastolic function index measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Vascular Function indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in number of heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Specific disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cell counts in induced sputum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Alive and Progression Free
Endpoint domain: Mortality/survival
Primary endpoint: Events of Deep Vein Thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical PE (Pulmonary Embolism) Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intravaginal Ejaculatory Latency Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean simple endoscopic scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in portal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reading performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HIV infection risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major Mobility Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of family aggregation of pulmonary ground glass nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Responsiveness to IGF1R therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of response size of selected ERPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variability of response timing of selected ERPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: WPAI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bacterial Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number and types of drug related problems identified
Endpoint domain: Adverse events/effects
Primary endpoint: midwifery students' performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete metabolic response rate (MCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased risk of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eating behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach maximum observed concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory phenomena severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-response on CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score from Bayley Scales of Infant and Toddler Development testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional anisotropy(FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: the value of Amplitude of Low Frequency Fluctuation(ALFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biopsy-proven rejection episodes (BPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient post-Liver Transplantation survival
Endpoint domain: Mortality/survival
Primary endpoint: Patient-reported Stiffness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: β diversity of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deviating physical examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal 12-lead ECG results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: abnormal laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infusion related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Transverse translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostasis Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleeplessness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: # of patients that develop non-communicable diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between errors in Spatial working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Strategy in Spatial working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Willingness to Receive the HPV Vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of NPC patients with high somatostatin receptor density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Short term immune response following immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: working memory condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visuospatial abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Western Ontario & McMaster Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning